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OBJECTIVE: This research contributes to the inﬂuence
of cost on clinical decision-making. It analyses the impact
of cost to the patient rather than knowledge of drug
prices/costs on physicians’ decisions. It is based on 
ﬁndings from a physicians’ cost sensitiveness analysis
from the BIOMED/ENDEP project called patient 
charges and decision making behaviors of consumers and
physicians.
METHODS: A “reversed” conjoint value analysis (CVA)
is run on four patient attributes rather than product
attributes. The four attributes are patient affordability,
patient demand for cheaper drugs, severity of disease and
risk factors and patient expenses on other diseases. The
design allows a large number of levels for analyzing
potential shifts with complex cost-sharing arrangements.
Randomization of cases is ensured through a stepwise
procedure and 39 clinical cases out of 54 are discarded.
High levels of orthogonality are achieved (over 90% of
D efﬁciency) and only main effects are calculated. The
questionnaire is administered on four randomized
samples of 100 physicians in France, the UK, Finland and
Italy. The statistical analysis is run with a linear regres-
sion better suited for a rate-scale dependent variable.
RESULTS: Average physician’s utilities and an outcome
measure of drug prescribing are presented. Patient
demand for cheaper drugs and patient expenses on other
diseases are the most important attributes to inﬂuence
physicians’cost sensitivity. Cost sensitive physicians shift
from top selling drugs to cheaper drugs under patient
needs. Some links with drug appropriateness issues are
also highlighted.
CONCLUSIONS: The analysis is useful for policy makers
interested in prescription drug policy, especially in the
USA, where direct health care outspendings increase at 
a fast rate. It provides evidence for educational policies
and behavioral changes towards physicians and patients,
and a potential decision tool to drug beneﬁt managers in
order to predict prescribing cost in response to different
cost-sharing policies.
HEALTH POLICY—Quality of Life Presentations
PHP49
PHP50
HEALTH-RELATED QUALITY OF LIFE IN
HEMOPHILIA AND VON WILLEBRAND’S
DISEASE: MEASUREMENT PROPERTIES OF THE
HEALTH UTILITIES INDEX
Horsman JR, Furlong W, Barr RD, Sek J, Pai M,Walker I
McMaster University, Hamilton, ON, Canada
OBJECTIVES: To test the hypotheses that increasing
severity of factor VIII/IX deﬁciency in hemophiliacs 
and severity in von Willebrand’s Disease (VWD) patients
would be associated with lower health-related quality of
life (HRQL), and that hepatitis and HIV positivity would
further impair HRQL.
METHODS: A cross-sectional mail survey of a popula-
tion-based cohort from a regional hemophilia program 
in Ontario Canada was conducted of mild, moderate and
severe hemophiliacs and T1, T2 and T3 VWD patients
over 13 years of age. Patients reported their health status
“during the past 4 weeks” using a standard Health 
Utilities Index (HUI) 15-item questionnaire. Responses
were mapped to the generic HUI Mark 3 (HUI3) health-
status classiﬁcation system. Eight single-attribute mor-
bidity scores and one HRQL score were determined using
published utility functions.
RESULTS: The response rate was > 85% (101 of 115
hemophiliacs, 28 of 36 VWD patients). Morbidity was
greater in hemophiliacs and VWD than in the general
population (p < 0.001). For hemophiliacs the burden cor-
related with the category of disease, mild < moderate <
severe (p < 0.05). Hepatitis and HIV positivity imposed
additional burdens, mainly in ambulation and pain (p <
0.005). VWD female patients reported important burdens
in emotion, cognition and pain with a mean HRQL score
lower than for severe hemophiliacs (0.55 vs. 0.65). The
differences in mean HUI3 scores between males and
females were large (> 0.14) for HRQL (p < 0.05) as well
as for emotion (p < 0.05), cognition (p = 0.01) and pain
(p = 0.01).
CONCLUSIONS: Despite improvements in the effective-
ness and utilization of clotting factor concentrates, hemo-
philiacs continue to suffer a serious burden of morbidity
providing a basis for future economic evaluation of 
the costs and consequences of health care interventions.
The heavy burden of morbidity reported by females with
VWD provides direction for support and therapeutic
intervention given little consideration to date. Evidence
supports the construct validity of the HUI3.
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